New Frontier in Antiviral Drugs for Disorders of the Respiratory System

Background: COVID-19 is still soaring, and the new delta COVID-19 variant is on the rise and spreading around the world. Objective: We conducted a patent analysis to better understand the therapeutic strategy developed for antivirals available for the disorders of the respiratory system. Materials and Methods: European granted patents filed from January 2002 to June 2021 were analyzed. We used a combination of International patent classification (IPC) “A61p31/12” and “A61p11/00” to search the relevant documents. Results: Our study showed R of antiviral drugs for disorders of the respiratory system to be decreasing over the past 20 years. Chemical drugs showed various chemical structures. The development of chemical drugs or herbal medicines appeared to commence earlier than the biological products. Also, the results indicated that large global companies play a leading role in developing kinase inhibitors as chemical drugs. Conclusion: There are three strategies for developing antiviral drugs for the disorders of the respiratory system, including chemical drugs, herbal medicines or natural products, and biological products. Herbal medicines may provide a new insight and approach to developing antiviral drugs for disorders of the respiratory system. A combination of chemical drugs and natural products may be a promising therapeutic method for treating patients with COVID- 19.